Chase Corporation Acquires Hylomar
Strengthens Presence in High-Performance Sealants and Adhesives
Hylomar has over 60 years of experience in developing and manufacturing high-performance sealing and adhesive materials for demanding industrial and engineering applications. The company's product portfolio includes non-setting gasketing and jointing compounds, silicone sealants, anaerobic adhesives, structural adhesives, and sealing putties.
"The acquisition expands our presence in specialty sealing and adhesive materials," said
Hylomar employees will join Chase's broad-based ownership program, which provides employees with the opportunity to participate in the benefits of equity ownership.
About Chase Corporation
Founded in 1946, Chase Corporation is a global leader in the development and manufacture of engineered materials for high-reliability applications. Its products deliver enhanced performance and durability in demanding environments, serving customers in the industrial, infrastructure, and electronics sectors.
For more information, visit www.chasecorp.com.
About Hylomar
Hylomar manufactures a wide range of high-performance sealants and adhesives used by leading OEM's in the transportation, aerospace, power generation / distribution, electronics, white goods, and general engineering sectors. Hylomar's product portfolio includes advanced non-setting gasketing & jointing compounds and specialized formulations specified by various aero-engine manufacturers including Rolls-Royce and Pratt & Whitney.
For more information, visit www.hylomar.com.
Media Contact:
Corporate Communications
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/chase-corporation-acquires-hylomar-302858547.html
SOURCE CHASE CORPORATION
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share